High Expression of Stem Cell Marker ALDH1 is Associated with Reduced BRCA1 in Invasive Breast Carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2973-2978

  Madjd, Zahra ^a,b   Ramezani, Babak ^a   Molanae, Saadat ^a   Asadi Lari, Mohsen ^b  

^a MILAD HOSPITAL   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ALDH1; Breast cancer; Cancer stem cells

Indexed keywords

EID: 84874078363     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2973     Document Type: Article

References (35)

1. Abraham BK, Fritz P, McClellan M, et al (2005). Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res, 11, 1154-9.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100, 3983-8.
3. Balicki D (2007). Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell, 1, 485-7.
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 65, 10946-51.
5. Costa FF, Le Blanc K, Brodin B (2007). Cancer/testis antigens, stem cells and cancer. Stem Cells, 25, 707-11.
6. Diehn M, Clarke MF (2006). Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst, 98, 1755-7.
7. Ellis IO, Galea M, Broughton N, et al (1992). Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology, 20, 479-89.
8. Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology, 19, 403-10.
9. Eyler CE, Rich JN (2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol, 26, 2839-45.
10. Fang D, Nguyen TK, Leishear K, et al (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res, 65, 9328-37.
11. Ginestier C, Hur MH, Charafe-Jauffret E, et al (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-67.
12. Ginestier C, Wicha MS (2007). Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res, 9, 109.
13. Glinsky GV, Berezovska O, Glinskii AB (2005). Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest, 115, 1503-21.
14. Heerma van Voss MR, Van der Groep P, Bart J, Van der Wall E, Van Diest PJ (2011). Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol, 34, 3-10.
15. Jiang F, Qiu Q, Khanna A, et al (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res, 7, 330-8.
16. Kunju LP, Cookingham C, Toy KA, et al (2011). EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol, 24, 786-93.
17. Li C, Heidt DG, Dalerba P, et al (2007). Identification of pancreatic cancer stem cells. Cancer Res, 67, 1030-7.
18. Li X, Lewis MT, Huang J, et al (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst, 100, 672-9.
19. Liu S, Ginestier C, Charafe-Jauffret E, et al (2008). BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA, 105, 1680-5.
20. Madjd Z, Mehrjerdi AZ, Sharifi AM, et al (2009). CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun, 9, 4.
21. Madjd Z, Karimi A, Molanae S, Asadi-Lari M (2011). BRCA1 protein expression level and CD44+ phenotype in breast cancer patients. Cell Journal, 13, 155-62.
22. Matsui W, Huff CA, Wang Q, et al (2004). Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332-6.
23. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985). Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med, 109, 716-21.
24. Morimoto K, Kim SJ, Tanei T, et al (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci, 100, 1062-8.
25. Nalwoga H, Arnes JB, Wabinga H, Akslen LA (2010). Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer, 102, 369-75.
26. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL (2010). In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol, 176, 2131-8.
27. Neumeister V, Rimm D (2010). Is ALDH1 a good method for definition of breast cancer stem cells? Breast Cancer Res Treat, 123, 109-11.
28. Phillips TM, McBride WH, Pajonk F (2006). The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst, 98, 1777-85.
29. Pinder SE, Ellis IO, Galea M, et al (1994). Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology, 24, 41-7.
30. Resetkova E, Reis-Filho JS, Jain RK, et al (2010). Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat, 123, 97-108.
31. Trimboli AJ, Cantemir-Stone CZ, Li F, et al (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461, 1084-91.
32. Vasiliou V, Pappa A, Petersen DR (2000). Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact, 129, 1-19.
33. Visvader JE, Lindeman GJ (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 8, 755-68.
34. Yoshioka T, Umekita Y, Ohi Y, et al (2011). Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study. Histopathology, 58, 608-16.
35. Zhou L, Jiang Y, Yan T, et al (2010). The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat, 122, 795-801.